RI
DSGN icon

RTW Investments’s Design Therapeutics DSGN Stock Holding History

RTW Investments’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,512,986
Closed -$5.93M – 66
2023
Q3 		$5.93M Buy
2,512,986
+949,955
+61% +$4.43M 0.13% 54
2023
Q2 		$9.85M Buy
+1,563,031
New +$9.56M 0.19% 49

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments's DSGN Position: Q4 2023 in Review

RTW Investments sold out of Design Therapeutics (DSGN) in Q4 2023, closing a stake of 2,512,986 shares — an estimated $5.93M sold.

RTW Investments first reported a position in DSGN in Q2 2023 and held it in 2 quarters. The position peaked at $9.85M in Q2 2023. 88 funds tracked by Wall St. Rank hold DSGN as of Q4 2023.

  • RTW Investments reported no remaining Design Therapeutics position as of Q4 2023 after selling out during the quarter.
  • RTW Investments sold 2,512,986 Design Therapeutics shares in Q4 2023, an estimated $5.93M.
  • RTW Investments first reported a position in Design Therapeutics in Q2 2023 and held it in 2 quarters.
  • RTW Investments's Design Therapeutics position peaked at $9.85M in Q2 2023.
  • 88 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2023.

Based on RTW Investments's 13F filing for Q4 2023, filed 14 Feb 2024.